U.S. Department of Health and Human Services BARDA Industry Day Presentation Washington, DC

U.S. Department of Health and Human Services

BARDA Industry Day Presentation

Forward Looking Statements

MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES,

INCLUDING WHETHER AND WHEN OUR HEMOPURIFIER AND OTHER PRODUCT OFFERINGS ARE SUCCESSFULLY DEVELOPED AND INTRODUCED,

MARKET ACCEPTANCE OF OUR HEMOPURIFIER AND OTHER PRODUCT OFFERINGS, REGULATORY DELAYS, MANUFACTURING DELAYS, AND OTHER

RISKS DETAILED IN OUR SEC FILINGS ACCESSIBLE ONLINE AT WWW.SEC.GOV OR WWW.AETHLONMEDICAL.COM

A Broad-Spectrum Antiviral Platform Technology

The BARDA Strategic Objectives

To identify and support the development of innovative

Strategies that address traditional, enhanced, emerging,

and advanced threats

Adjunct or adjuvant therapies that improve

countermeasure performance

The first medical device to selectively remove infectious

viruses and immunosuppressive toxins from circulation

Leverages the established infrastructure

of 90,000+ U.S. based dialysis stations

Additional Infrastructure to Deliver

Hemopurifier Therapy

CRRT machines already located in hospitals

and clinics throughout the U.S.

Portable pump configurations

1. Separation of particles below

250nm from the circulatory

2. Immobilized lectin affinity agents

then selectively bind to unique

high mannose structures resident

on viral glycoproteins that coat

Lectin Binding Sites

Dual Benefit of Action

Antiviral & Immunotherapeutic

Rapid real-time clearance of

infectious viral pathogens

Fulfills unmet medical need of

clearing virally-shed

Regulatory Path: Device vs. Drug

70 human treatment experiences

IDE on file with FDA

GMP manufacturing already established

Substantial viral load reductions in human HIV and HCV studies

Follow-on HCV studies initiated

Proven broad-spectrum capabilities against bioterror and pandemic

Selected Quick Facts

In Vitro Confirmations Against

Bioterror and Pandemic Threats

The Hemopurifier improves public

health emergency preparedness against:

"The Aethlon Hemopurifier is the

only strategy to address the

breadth of pathogens that could

be weaponized as agents of

First Deputy Director of Biopreparat

Known naturally occurring threats such as

Smallpox, Ebola, Marburg, Lassa

The Hemopurifier serves as an adjunct to improve the

benefit of established and candidate treatment strategies

The Hemopurifier provides a first-line countermeasure

strategy against threats not addressed by drug or vaccines

Traditional threats that have been genetically modified to

enhance virulence or circumvent drug and vaccine therapies

The Hemopurifier serves as a first-line countermeasure

against enhanced agents

Provides adjunct strategy to strengthen benefit of

therapies proven safe and effective against similar

Assists in characterization of enhanced agents

Previously unrecognized pathogens that occur naturally such as

SARS or future strains of pandemic influenza

The Hemopurifier is a candidate first-line

countermeasure against emerging pathogens

Provides adjunct strategy to strengthen benefit of

therapies proven safe and effective against similar

Assists in early characterization of emerging

Novel pathogen artificially engineered to bypass traditional drug

and vaccine countermeasures or enhance disease severity

The Hemopurifier represents the sole first-line

treatment strategy against advanced agents

Assists in early characterization of advanced agents

The Hemopurifier also provides a therapeutic

mechanism to address at-risk populations for whom drug

and vaccine therapies may be contraindicated

Stockpile Implications

Refrigeration not required

Therapeutic demand in HCV, HIV, and cancer provides

replenishing FIFO stockpile

Selected Examples of Therapeutic Filtration

Marburg Plasmapheresis (1990)

Anthrax Toxin Plasmapheresis (2001)

2001 Anthrax Survivor

"It's hard to say what saved me, but one

of the things was plasmapheresis.

Honestly, without it, I would be dead."

Anthrax infected postal worker

An Adaptable Platform Technology

The Hemopurifier provides a platform for multi-use product

development and manufacture

Interchanging affinity agents within our core Hemopurifier

cartridge expands targets beyond viral threats

Bacterial threats such as Anthrax could be addressed through